Relapsed/Refractory Clinical Trial
Official title:
A Phase 1b/2, Open-label, Multi Cohort Trial of Tazemetostat in Combination With Various Treatments in Subjects With Relapsed or Refractory Hematologic Malignancies
This phase 1b/2 trial studies how safely the EZH2 inhibitor tazemetostat works with other therapies in various hematological malignancies. Tazemetostat has been found to be a safe and effective drug that works in patients with relapsed refractory follicular lymphoma. Giving tazemetostat in combination with other treatments may work better in treating patients with hematological malignancies and may improve disease response and durability of response.
n/a
| NCT number | NCT05205252 |
| Study type | Interventional |
| Source | Epizyme, Inc. |
| Contact | Clinical Trial |
| Phone | 1 (855) 500-1011 |
| [email protected] | |
| Status | Recruiting |
| Phase | Phase 1/Phase 2 |
| Start date | December 22, 2021 |
| Completion date | May 2028 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02952573 -
Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement
|
Phase 2 | |
| Completed |
NCT03439280 -
A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)
|
Phase 1/Phase 2 |